Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00475306 · ClinicalTrials.gov registry record · Phase 4
The Montefiore Metoclopramide Study
A Phase 4 study of Nausea and Extrapyramidal Symptoms, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 289
- Enrollment target
- 1
- Study location
NCT00475306: Completed Phase 4 study of Nausea and Extrapyramidal Symptoms, sponsored by Montefiore Medical Center.
NCT00475306 is a Phase 4 study of Nausea and Extrapyramidal Symptoms that has completed, run by Montefiore Medical Center. The registered enrollment target is 289 participants, above the 227-participant average among 17 other Nausea trials with a reported enrollment target (27% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00475306, a Phase 4 study of Nausea and Extrapyramidal Symptoms, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 289 participants
- Enrollment target
- 1
- Study location
Study Summary
Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea, vomiting, and migraine headaches in Emergency Departments. However, little research has focused on the optimal dose of metoclopramide for treatment of nausea in the emergency department. We propose a randomized, double-blind, placebo controlled trial to investigate the optimal dose of metoclopramide for treatment of nausea.
Primary Outcome
Patients were asked to report their level of nausea on a scale for 0 to 10, with 0 representing no nausea and 10 the worst nausea imaginable
Conditions Studied
Interventions
- DRUG Placebo
- DRUG metoclopramide 10 mg
- DRUG Diphenhydramine 25 mg
- DRUG Metoclopramide 20 mg
Study Locations (1)
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 289 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-02 |
| Phase | Phase 4 |
What the finished NCT00475306 record still lists
NCT00475306 is an interventional study that assigns participants to a tested intervention. The registered 289 participants enrollment target is mid-sized for trials with a published cap, above the 227-participant average among 17 other Nausea trials with a reported enrollment target (27% higher).
The record links to 2 conditions, with Nausea appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT00475306 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00475306 about?
NCT00475306 is a clinical study titled "The Montefiore Metoclopramide Study". Metoclopramide is a dopamine antagonist frequently used for the treatment of nausea, vomiting, and migraine headaches in Emergency Departments. However, little research has focused on the optimal dose of metoclopramide for treatment of nausea in the emergency department. We propose a randomized, dou...
What is the current status of trial NCT00475306?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 289 participants. The study started on 2007-05. Estimated completion is 2008-02.
What conditions does trial NCT00475306 study?
This clinical trial studies the following conditions: Nausea, Extrapyramidal Symptoms.
What interventions are being tested in trial NCT00475306?
The interventions under investigation include: Placebo (DRUG), metoclopramide 10 mg (DRUG), Diphenhydramine 25 mg (DRUG), Metoclopramide 20 mg (DRUG).
Who is sponsoring clinical trial NCT00475306?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00475306 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00475306's enrollment target sits among peer trials
289 2nd of 17 the highest of 17 other Nausea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nausea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aprepitant Versus Ondansetron in Preoperative Triple-therapy Treatment of Nausea and Vomiting
COMPLETED · Phase 4
-
Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department
COMPLETED · Phase 4
-
Inhaled Isopropyl Alcohol for Treatment of Nausea
RECRUITING · Phase 2
-
Alternate Nostril Breathing (ANB) for 1st Trimester Nausea and Vomiting
RECRUITING · NA
-
Antiemetic Fosaprepitant To Remedy Nausea and Vomiting
RECRUITING · Phase 2
-
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06465199 · 289 participants · Phase 1
Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
- NCT00775476 · 290 participants · Phase 2
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
- NCT01874197 · 290 participants · NA
Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic
- NCT04331353 · 290 participants · NA
The Allergen Reduction and Child Health Study (ARCHS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia